Sustanon steroid ® 30/70 human insulin produced by recombinant DNA technology. Insulin is a combination of short and intermediate-acting 30/70. Interacts with the specific receptor cytoplasmic outer cell membrane to form insulin-receptor complex stimulates intracellular processes, in Vol. H. The synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen, etc.). Reduction in blood glucose is due to an increase of intracellular transport, absorption and assimilation of amplification tissues, stimulation of lipogenesis, glikogenogeneza, and decrease liver glucose production rate al.The duration of action of insulin formulations is mainly due to absorption rate, which depends on several factors (e.g., dose, method and place of introduction), and therefore the action of insulin profile is subject to considerable variations as different people, and at the same human.Profile action after subcutaneous injection (approximate figures): onset of action within 30 minutes, the maximum effect – between 6 and 12 hours, the duration of action – 18-24 hours.
Completeness beginning insulin absorption and the effect depends on the site of injection (abdomen, thigh, buttocks), the dose (amount of injected insulin), insulin concentration in the formulation, etc. distributed in the body unevenly.; It does not cross the placental barrier and into breast milk. It destroyed insulinase mainly in the liver and kidneys. Excreted by the kidneys (30-80%).
– Individual hypersensitivity to insulin or any of the components of the drug
Dosing and Administration
sustanon steroid 30/70 is intended for subcutaneous administration. Dose determined by the physician individually in each case, on the basis of blood glucose levels. On average, the daily dose ranges from 0.5 IU / kg to 1 IU / kg body weight (depending on the individual patient and blood glucose level).
Temperature of insulin must comply room.
sustanon steroid 30/70 is usually administered subcutaneously in the thigh. Injections can be made in the abdominal wall, the buttocks or the deltoid region of the shoulder muscles.
It is necessary to change the injection site within the anatomical region to prevent the development of lipodystrophy.
Side effects caused by the effect on carbohydrate metabolism: hypoglycemic state (pale skin, increased sweating, palpitations, tremor, hunger, excitement, paresthesia in the mouth, headache). Severe hypoglycemia may lead to the development of hypoglycemic coma.
Allergic reactions: seldom – skin rash, angioedema, rarely -anafilaktichesky shock.
Local reactions: redness, swelling and itching at the injection site, with prolonged use – lipodystrophy at the injection site.
Other: edema, transient refractive error (usually at the beginning of therapy).
In case of overdose may develop hypoglycaemia.
Treatment: mild hypoglycemia, the patient can remove himself, taking into sugar or carbohydrate-rich foods. Therefore, patients with diabetes should always carry sugar, sweets, biscuits or sugary fruit juice.
In severe cases, loss of consciousness of the patient, intravenous 40% dextrose; intramuscularly, subcutaneously, intravenously – glucagon. After regaining consciousness of the patient is recommended to take food rich in carbohydrates, to prevent recurrence of hypoglycemia.
The interaction with other drugs
There are a number of drugs that affect the demand for insulin.
Hypoglycemic effect of insulin increase the oral hypoglycemic drugs, monoamine oxidase inhibitors, angiotensin-converting enzyme, carbonic anhydrase inhibitors, non-selective beta-blockers, bromocriptine, octreotide, sulphonamides, anabolic steroids, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, lithium preparations , formulations containing ethanol. Hypoglycemic effect of insulin impaired oral contraceptives, steroids, thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, danazol, clonidine, calcium channel blockers, diazoxide, morphine, phenytoin, nicotine. Under the influence of reserpine and salicylates may as a weakening or strengthening of the drug.
Do not use sustanon steroid ® 30/70, if after shaking the suspension becomes uniformly white and cloudy.
Against the background of insulin therapy requires constant monitoring of blood glucose levels. The causes of hypoglycemia than insulin overdose can be: the replacement of the drug, skipping meals, vomiting, diarrhea, increased physical activity, disease, reducing the need for insulin (human liver and kidneys, hypofunction of the adrenal cortex, pituitary or thyroid gland), change the injection site, as well as interaction with other drugs.
Incorrect dosing or breaks in the introduction of insulin, particularly in patients with Type 1 diabetes, may cause hyperglycemia. Usually the first symptoms of hyperglycaemia develop gradually over several hours or days. These include the emergence of thirst, frequent urination, nausea, vomiting, dizziness, redness and dryness of the skin, dry mouth, loss of appetite, the smell of acetone in exhaled air. If left untreated, hyperglycemia in diabetes mellitus type 1 can lead to life-threatening diabetic ketoacidosis.
The dose of insulin should be corrected with thyroid disorders, Addison’s disease, hypopituitarism, violations of liver and kidney function and diabetes in individuals older than 65 years.
Insulin Dose adjustment may also be required if the patient increases the intensity of physical activity or change the habitual diet.
Concomitant illness, especially infections and conditions accompanied by fever, increase the need for insulin.
The transition from one species to another insulin should be done under the control of blood glucose levels.
The drug reduces the tolerance to alcohol.
In connection with the possibility of some precipitation to catheters, it is not recommended to use the drug in insulin pumps.
Effects on ability to drive vehicles and management mechanisms
In connection with the primary purpose of insulin, changing its appearance or the presence of significant physical or mental stress, may reduce the ability to drive a car or to the management of a variety of mechanisms, as well as studies in other potentially hazardous activities that require attention and speed of mental and motor responses.
suspension for subcutaneous administration of 100 IU / ml
10 ml in a bottle of colorless neutral glass (Type I USP), a sealed rubber stopper with aluminum and plastic running-cap
1 bottle in a cardboard box with instructions for use
3ml cartridge in a neutral colorless glass syringe for use with pen-sustanon steroid ® Pen.
On 5 cartridges in blister AL / PVC
1 blister in a cardboard box with instructions for use weight loss injections side effects hcg vials and hmg treatment of male infertility